Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|March 17, 2020
ClinCapture to Provide Free EDC for Researchers Investigating COVID-19 Treatment
Advertisement
ClinCapture, Inc., a provider for Electronic Data Capture (EDC) systems and eClinical solutions, announced that it will begin offering EDC at no cost for specific clinical trials investigating COVID-19 Coronavirus. The decision to offer free EDC for BioPharma and Diagnostic companies conducting COVID-19 clinical trials was announced after the World Health Organization issued a statement that the confirmed number of COVID-19 cases has surpassed 100,000 globally.
ClinCapture is inspired by the response time, organization, and dedication to find solutions for COVID-19 demonstrated within the clinical research industry and would like to help these companies by offering free EDC for their trials. ClinCapture will be providing its Captivate EDC through the philanthropic Weidley's Wish program which normally provides EDC to non-profit organizations conducting Rare Disease/Orphan Disease trials.
"We are in a unique position in a unique point in history," said ClinCapture CEO Scott Weidley. "Our commitment to act now will have a dramatic effect on our ability to help in the future."
ClinCapture's Captivate EDC is a fully validated, cloud-hosted system designed to offer researchers more insight into their clinical data in order to bring treatments to market faster.
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
3
Where AI Governance in Clinical Development Falls Short
4
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
5